TY - JOUR
T1 - Patient-reported impact of symptoms in schizophrenia scale (PRISS)
T2 - development and validation
AU - Moreno-Küstner, Berta
AU - Fábrega-Ruz, Julia
AU - Gonzalez-Caballero, Juan Luis
AU - Reyes-Martin, Sara
AU - Ochoa, Susana
AU - Romero-Lopez-Alberca, Cristina
AU - Cid, Jordi
AU - Vila-Badia, Regina
AU - Frigola-Capell, Eva
AU - Salvador-Carulla, Luis
N1 - Funding Information:
The study was supported by the Huxiang Youth Talent Support Foundation of China (2020RC3059).
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Funding Information:
The study was supported by the Huxiang Youth Talent Support Foundation of China (2020RC3059).
Funding Information:
This study has been funded by the ‘Instituto de Salud Carlos III’ through the project PI16/00647 and co-funded by the European Regional Development Fund (FEDER) ‘A way to make Europe’. We would like to thank all the researchers and clinicians who have participated in this study. We also thank the CERCA Programme, Generalitat de Catalunya. In addition, we would like to acknowledge the authors of the Spanish version of the PANSS (Victor Peralta and Manuel Cuesta).
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Background: We report the psychometric properties of the Patient-Reported Impact of Symptoms in Schizophrenia Scale (PRISS), which assesses the impact of subjective experiences or qualia in outpatients with this condition. Methods: A cross-sectional study was carried out in 162 patients diagnosed with schizophrenia in Spain. The PRISS measures the presence, frequency, concern and interference with daily life of self-reported experiences related to the main symptoms observed in these patients. The psychometric analysis included test-retest reliability, internal consistency and structural and convergent validity. Results: The 28-item PRISS showed good test-retest reliability as 64.3% of the intraclass correlation coefficient values were between 0.40 and 0.79, which were statistically significant (p < 0.01). Analysis of the structural validity revealed a three-factor structure, (1) productive subjective experiences, (2) affective-negative subjective experiences and (3) excitation, which accounted for 56.11% of the variance. Of the Pearson's correlation coefficients analysed between the PRISS and the Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Negative Symptoms (SANS) and World Health Organization Disability Assessment Schedule (WHO-DAS), 72.2% were statistically significant (p < 0.05) and ranged from 0.38–0.42, 0.32–0.42 and 0.40–0.42, respectively. Conclusion: Our results indicate that the PRISS appears to be a brief, reliable and valid scale to measure subjective experiences in schizophrenia and provides valuable information complementary to clinical evaluation.
AB - Background: We report the psychometric properties of the Patient-Reported Impact of Symptoms in Schizophrenia Scale (PRISS), which assesses the impact of subjective experiences or qualia in outpatients with this condition. Methods: A cross-sectional study was carried out in 162 patients diagnosed with schizophrenia in Spain. The PRISS measures the presence, frequency, concern and interference with daily life of self-reported experiences related to the main symptoms observed in these patients. The psychometric analysis included test-retest reliability, internal consistency and structural and convergent validity. Results: The 28-item PRISS showed good test-retest reliability as 64.3% of the intraclass correlation coefficient values were between 0.40 and 0.79, which were statistically significant (p < 0.01). Analysis of the structural validity revealed a three-factor structure, (1) productive subjective experiences, (2) affective-negative subjective experiences and (3) excitation, which accounted for 56.11% of the variance. Of the Pearson's correlation coefficients analysed between the PRISS and the Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Negative Symptoms (SANS) and World Health Organization Disability Assessment Schedule (WHO-DAS), 72.2% were statistically significant (p < 0.05) and ranged from 0.38–0.42, 0.32–0.42 and 0.40–0.42, respectively. Conclusion: Our results indicate that the PRISS appears to be a brief, reliable and valid scale to measure subjective experiences in schizophrenia and provides valuable information complementary to clinical evaluation.
KW - patient-reported outcome
KW - patient-reported outcome measure
KW - schizophrenia
KW - subjective experiences
UR - http://www.scopus.com/inward/record.url?scp=85125443659&partnerID=8YFLogxK
U2 - 10.1111/acps.13417
DO - 10.1111/acps.13417
M3 - Article
C2 - 35188673
AN - SCOPUS:85125443659
SN - 0001-690X
VL - 145
SP - 640
EP - 655
JO - Acta Psychiatrica Scandinavica
JF - Acta Psychiatrica Scandinavica
IS - 6
ER -